Stock data
TScan Therapeutics, Inc. (TCRX)
TScan Therapeutics, Inc. (TCRX) reported revenue of US$10.32M and net income of -US$129.77M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$10.32M | — | -US$135.81M | -US$129.77M | — |
| 2024 | US$2.82M | — | -US$134.82M | -US$127.50M | — |
| 2023 | US$21.05M | — | -US$93.46M | -US$89.22M | — |
| 2022 | US$13.54M | — | -US$66.64M | -US$66.22M | — |
| 2021 | US$10.14M | — | -US$48.64M | -US$48.62M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$1.05M | -US$30.36M | — |
| 2026-03-31 | US$0.98M | -US$28.67M | — |
| 2025-12-31 | US$2.57M | -US$22.98M | — |
| 2025-09-30 | US$2.51M | -US$35.71M | — |
| 2025-06-30 | US$3.08M | -US$36.95M | — |
| 2025-03-31 | US$2.17M | -US$34.13M | — |
| 2024-12-31 | US$0.67M | -US$35.81M | — |
| 2024-09-30 | US$1.05M | -US$29.89M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.